Latest News and Press Releases
Want to stay updated on the latest news?
-
Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain London, UK, 07 March 2024 – Persica Pharmaceuticals Ltd, a privately held,...
-
Pune, India, Jan. 10, 2022 (GLOBE NEWSWIRE) -- The rising prevalence of chronic pain across the world is expected to drive the global chronic lower back pain treatment market. As per the National...
-
CLEVELAND, March 15, 2021 (GLOBE NEWSWIRE) -- A novel theory recently published in the Journal of Pain Research proposes mechanisms by which a 60-day treatment using percutaneous peripheral nerve...
-
CLEVELAND, March 02, 2021 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, announced publication of clinical data evaluating the impact of...
-
New York City, NY , Nov. 23, 2020 (GLOBE NEWSWIRE) -- The Back Pain Wizard is a system designed to reinstate muscle balance by releasing the trapped tension in the back and stabilizing the right...
-
ZTlido® gross sales grew from approximately $1 million in March to $2.4 million in April and $3.3 million in MaySP-102 pivotal phase 3 trial remains on track for completion in H1 2020ZTlido® 5.4% (3 X...
-
CLEVELAND, Sept. 25, 2018 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, today announced that Christopher Gilmore, MD of Carolinas Pain...
-
SPRINT® is the First and Only Dual Lead Capable PNS Platform Company also provides first look at 12-month durability outcomes following 60-day SPRINT therapy CLEVELAND, Aug. 16, 2018 (GLOBE...
-
ESCONDIDO, Calif., June 30, 2014 (GLOBE NEWSWIRE) -- Being overweight forces the spine to absorb an extra burden and causes thousands of Americans to suffer lower back pain. Over time, those who are...
-
NEW YORK and MELBOURNE, Australia, Jan. 29, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced positive 12 month outcome results from the...